Assessment of the efficiency of treatment of patients with COVID-19 (literature review)

V.D. Moskaliuk; I.V. Balaniuk; M.O. Andrushchak; B.V. Sirota; L.M. Honcharuk; N.V. Chernetska; V.V.  Ilika

doi:10.26641/2307-0404.2024.1.300502

Authors

V.D. Moskaliuk Bukovinian State Medical University, Holovna str., 137, Chernivtsi, 58022, Ukraine https://orcid.org/0000-0002-4104-8153
I.V. Balaniuk Bukovinian State Medical University, Holovna str., 137, Chernivtsi, 58022, Ukraine https://orcid.org/0000-0003-1146-4065
M.O. Andrushchak Bukovinian State Medical University, Holovna str., 137, Chernivtsi, 58022, Ukraine https://orcid.org/0000-0001-5003-9622
B.V. Sirota Bukovinian State Medical University, Holovna str., 137, Chernivtsi, 58022, Ukraine https://orcid.org/0000-0002-2654-5602
L.M. Honcharuk Bukovinian State Medical University, Holovna str., 137, Chernivtsi, 58022, Ukraine https://orcid.org/0000-0002-5761-1238
N.V. Chernetska Bukovinian State Medical University,Holovna str.,137,Chernivtsi,58022, Ukraine https://orcid.org/0000-0002-5156-1313
V.V. Ilika Bukovinian State Medical University, Holovna str., 137, Chernivtsi, 58022, Ukraine https://orcid.org/0000-0002-3714-9883

DOI:

https://doi.org/10.26641/2307-0404.2024.1.300502

Keywords:

COVID-19, treatment, patients

Abstract

WHO has recognized that COVID-19 is a global pandemic. In the conditions when COVID-19 continues to spread rapidly throughout the world, covering different groups of the population, and despite the fact that the existing standards of care for these patients are constantly updated, it is urgent to continue the search for new, more effective methods of treatment. Currently, the treatment of patients with COVID-19 remains difficult, since the drugs that have a harmful effect on the virus are at the stage of development and testing. Remdesivir, favipiravir, hydroxychloroquine with or without azithromycin, ivermectin, lopinavir/ritonavir were recommended among the agents for etiotropic therapy. But at present, the WHO notes that there is no evidence to recommend any specific antiviral treatment against COVID-19. The results obtained by conducting multicenter randomized clinical trials, which were conducted in 30 countries of the world and included 11,266 people of different ages, mostly adults and elderly. Unfortunately, the use of plasma from the blood of people who have contracted COVID-19 does not save the lives of seriously ill patients from the need to be connected to a ventilator and does not increase their chances of survival. This is also reported by WHO. In treatment, emphasis is placed on the application of pathogenetic therapy. The main measures of non-specific individual and collective prevention with the introduction of quarantine are briefly given. The article is intended mainly for doctors who work with patients with COVID-19 and contact persons. Treatment of patients with COVID-19, as a rule, is pathogenetic, since there are no specific antiviral drugs.. The decision regarding medical care in an outpatient clinic setting is made after a clinical assessment of the patient's condition and an assessment of home security. People who are at risk of developing complications should be referred for inpatient treatment.

References

Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367:1412-3. doi: https://doi.org/10.1126/science.367.6485.1412

Andreychyn MA, Nychyk NA, Zavidniuk NH, Iosyk II, Ischuk IS. [Treatment of patients with COVID-19 at the current stage. Infectious diseases]. Infektsiini khvoroby. 2020;3:5-17. Ukrainian. doi: https://doi.org/10.11603/1681-2727.2020.3.11548

Dubrov SO, Slavuta HB, Havrylenko OO, Poniatovskyi PL. [Nutritional therapy of patients with COVID-19. Overview of recommendations]. Pain, anaesthesia & intensive care. 2020;2(91):9-2. Ukrainian. doi: https://doi.org/10.25284/2519-2078.2(91).2020.205595

Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A. Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Current Opinion in Pharmacology. 2022;62:43-59. doi: https://doi.org/10.1016/j.coph.2021.11.002

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine. 2017;9(396):eaal3653. doi: https://doi.org/10.1126/scitranslmed.aal3653

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Jun 11;382(24):2327-36. doi: https://doi.org/10.1056/NEJMoa2007016

Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, et al. Remdesivir for the treatment of COVID‐19. Cochrane Database of Systematic Reviews. 2021;8:CD014962 doi: https://doi.org/10.1002/14651858.CD014962

FDA approves first treatment for COVID-19. U.S. Food and Drug Administration [Internet]. 2020 [cited 2023 Oct 21]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

Swadi AA, Shlash RF, Dibby HJ, Kadhim SAA, Abas MS. Efficacy of Tocilizumab among Severe COVID-19 patients. HIV Nursing. 2022;22(2):376-9.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192-8. doi: https://doi.org/10.1016/j.eng.2020.03.007

Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a rando-mized clinical trial. MedRxiv. 2020;03(17):20037432. doi: https://doi.org/10.1101/2020.03.17.20037432

Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square. 2020 Dec 28. doi: https://doi.org/10.21203/rs.3.rs-100956/v2

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine. 2020 May 7;382(19):1787-99. doi: https://doi.org/10.1056/NEJMoa2001282

Ramos-Rincon JM, López-Carmona MD, Cobos-Palacios L, López-Sampalo A, Rubio-Rivas M, Martín-Escalante MD, et al. Remdesivir in very old patients (≥80 years) hospitalized with COVID-19: real world data from the SEMI-COVID-19 Registry. Journal of Clinical Medicine. 2022;11(13):3769. doi: https://doi.org/10.3390/jcm11133769

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020;117(20):10970-5. doi: https://doi.org/10.1073/pnas.2005615117

Maraolo AE, Crispo A, Piezzo M, Di Gennaro P, Vitale MG, Mallardo D, et al. The use of tocilizumab in patients with COVID-19: a systematic review, meta-ana-lysis and trial sequential analysis of randomized controlled studies. Journal of clinical medicine. 2021;10(21):4935. doi: https://doi.org/10.3390/jcm10214935

Rianty AD. Studi in silico senyawa yang terkan-dung dalam tanaman artemisin (artemisia annua l.) sebagai anti SARS-COV-2 [dissertation]. Universitas BTH Tasi¬kmalaya; 2022.

Oliva JE, Zelaya S, Dominguez R. Opciones tera-péuticas contra el Covid-19. San Salvador; INS; 2021. 30 p.

Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Current Biology. 2020;30(7):1346-51. doi: https://doi.org/10.1016/j.cub.2020.03.022

Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARSCoV-2; Coronavirus Disease-19). Clinical and Experimental Pediatrics. 2020;63(4):119. doi: https://doi.org/10.3345/cep.2020.00493

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine. 2020;382:1199-207. doi: https://doi.org/10.1056/NEJMoa2001316

Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23. doi: https://doi.org/10.1016/S0140-6736(20)30154-9

Burke RM, Midgley CM, Dratch A, Fenster-sheib M, Haupt T, Holshue M, et al. Active monitoring of persons exposed to patients with confirmed COVID-19-United States, January-February 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69(9):245-6. doi: https://doi.org/10.15585/mmwr.mm6909e1

Guo ZD, Wang ZY, Zhang SF, Li X, Li L, Li C, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. Emerg Infect Dis. 2020;26(7):1583-91. doi: https://doi.org/10.3201/eid2607.200885

Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging Microbes & Infections. 2020;9(1):386-9. doi: https://doi.org/10.1080/22221751.2020.1729071

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Walrauch C, et al. Transmission of 2019- nCoV infection from an asymptomatic contact in Germany. New England Journal of Medicine. 2020;382(10):970-1. doi: https://doi.org/10.1056/NEJMc2001468

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosur-veillance. 2020;25(10):2000180. doi: https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000180

Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020 May;94:154-5. doi: https://doi.org/10.1016/j.ijid.2020.03.020

Hui DS. Super-spreading events of MERS-CoV infection. The Lancet. 2016;388(10048):942-3. doi: https://doi.org/10.1016/S0140-6736(16)30828-5

Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternalfetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020 Jul 1;144(7):799-805. doi: https://doi.org/10.5858/arpa.2020-0901-SA

Pneumonia of unknown cause – China. World Health Organization [Internet]. 2020 [cited 2023 Oct 21]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229

Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;1-5. doi: https://doi.org/10.1038/s41586-020-2196-x

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama. 2020;323(18):1775-6. doi: https://doi.org/10.1001/jama.2020.4683

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42. doi: https://doi.org/10.1001/jama.2020.2648

Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Medicine. 2020;46(5):837-40. doi: https://doi.org/10.1007/s00134-020-05979-7

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. doi: https://doi.org/10.1001/jama.2020.1585

Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):210-7. doi: https://doi.org/10.1148/radiol.2020200274

Zhu T, Wang Y, Zhou S, Zhang N, Xia L. A com-parative study of chest computed tomography features in young and older adults with Corona Virus disease (COVID-19). Journal of Thoracic Imaging. 2020 Jul;35(4):W97-W101. doi: https://doi.org/10.1097/RTI.0000000000000513

Soldati G, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, et al. Proposal for inter-national standardization of the use of lung ultrasound for COVID-19 patients; a simple, quantitative, reproducible method. Journal of Ultrasound in Medicine. 2020;7(39):1413-9. doi: https://doi.org/10.1002/jum.15285

Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases. 2020;6(20):697-706. doi: https://doi.org/10.1016/S1473-3099(20)30200-0

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020 Jul 28;71(15):732-9. doi: https://doi.org/10.1093/cid/ciaa237

Cortegiani A, Ingoglia G, Ippolito M, Giarra-tano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care. 2020;57:279-83. doi: https://doi.org/10.1016/j.jcrc.2020.03.005